Zodasiran for teens with inherited high cholesterol
Part of Genetic & congenital, Hormones & metabolism clinical trials.
This trial tests a new medicine called zodasiran for adolescents with a severe inherited form of high cholesterol. It aims to see if it can lower cholesterol levels that are hard to control with other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 12 and 17 years old.
- You weigh at least 35 kilograms (77 pounds).
- You have a confirmed diagnosis of homozygous familial hypercholesterolemia (a severe inherited form of high cholesterol).
- Your LDL cholesterol level is at least 116 mg/dL (3 mmol/L).
- Your blood sugar (HbA1c) is 9.5% or lower.
- You have not used certain other cholesterol-lowering drugs in the last few months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a one-time gene therapy (NGGT006) to treat a severe form of inherited high cholesterol that doesn't respond well to standard medications. It aims to lower cholesterol and reduce the risk of heart disease.
This trial tests a new medicine called inclisiran to lower very high cholesterol in children aged 2 to 12 who have a specific genetic condition (homozygous familial hypercholesterolemia, or HoFH). You may not need to change your current cholesterol treatments, and the study will check if inclisiran can help reduce your LDL cholesterol further.
This trial tests a medicine called inclisiran to lower high cholesterol in children ages 6 to 12 with a genetic condition called heterozygous familial hypercholesterolemia (HeFH). It may help children who still have high cholesterol despite taking other treatments.
This trial tests if a new medicine, lerodalcibep, can safely lower cholesterol in children ages 6 to 17 who have a genetic condition called heterozygous familial hypercholesterolemia (HeFH). It aims to help children whose cholesterol stays high despite taking standard cholesterol-lowering drugs.
This study tests a new injectable medication (SYH2070) designed to lower cholesterol in people with homozygous familial hypercholesterolemia—a genetic condition that causes extremely high cholesterol levels despite treatment. The goal is to see if this drug safely reduces cholesterol better than current options.
This trial tests a new drug, EDP167, for people with homozygous familial hypercholesterolemia (HoFH), a genetic condition that causes very high cholesterol. The goal is to see if EDP167 can lower 'bad' cholesterol (LDL-C).
Hear when a new Homozygous Familial Hypercholesterolemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.